|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
183,678,000 |
Market
Cap: |
4.30(B) |
Last
Volume: |
775,760 |
Avg
Vol: |
773,642 |
52
Week Range: |
$23.21 - $33.63 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 581 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Alkermes is a biopharmaceutical company. Co. has a portfolio of marketed products focused on central nervous system disorders such as addiction and schizophrenia and a pipeline of product candidates in the fields of neuroscience and oncology. Co.'s proprietary products include: ARISTADA, which is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia; ARISTADA INITIO, which is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults; and VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
35,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$815,735 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
10,417 |
15,666 |
21,104 |
96,962 |
Total Sell Value |
$292,740 |
$454,291 |
$626,511 |
$2,911,362 |
Total People Sold |
1 |
3 |
3 |
4 |
Total Sell Transactions |
1 |
3 |
5 |
8 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Jackson Blair Curtis |
EVP, Chief Operating Officer |
|
2024-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,693 |
157,249 |
|
- |
|
Nichols Christian Todd |
SVP, Chief Commercial Officer |
|
2024-02-22 |
4 |
D |
$28.91 |
$91,240 |
D/D |
(3,156) |
72,766 |
|
- |
|
Nichols Christian Todd |
SVP, Chief Commercial Officer |
|
2024-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,108 |
75,922 |
|
- |
|
Parisi Samuel Joseph |
VP, Finance (Interim PAO) |
|
2024-02-22 |
4 |
D |
$28.91 |
$26,250 |
D/D |
(908) |
8,665 |
|
- |
|
Parisi Samuel Joseph |
VP, Finance (Interim PAO) |
|
2024-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,114 |
9,573 |
|
- |
|
Jackson Blair Curtis |
EVP, Chief Operating Officer |
|
2024-02-20 |
4 |
D |
$30.39 |
$63,150 |
D/D |
(2,078) |
147,556 |
|
- |
|
Jackson Blair Curtis |
EVP, Chief Operating Officer |
|
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,680 |
149,634 |
|
- |
|
Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
|
2024-02-20 |
4 |
D |
$30.39 |
$48,806 |
D/D |
(1,606) |
275,739 |
|
- |
|
Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
|
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,461 |
277,345 |
|
- |
|
Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
|
2024-02-20 |
4 |
D |
$30.39 |
$90,988 |
D/D |
(2,994) |
156,376 |
|
- |
|
Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
|
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,177 |
159,370 |
|
- |
|
Nichols Christian Todd |
SVP, Chief Commercial Officer |
|
2024-02-20 |
4 |
D |
$30.39 |
$41,908 |
D/D |
(1,379) |
68,814 |
|
- |
|
Nichols Christian Todd |
SVP, Chief Commercial Officer |
|
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,901 |
70,193 |
|
- |
|
Brown Iain Michael |
SVP, Chief Financial Officer |
|
2024-02-20 |
4 |
D |
$30.39 |
$52,423 |
D/D |
(1,725) |
109,154 |
|
- |
|
Brown Iain Michael |
SVP, Chief Financial Officer |
|
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,680 |
110,879 |
|
- |
|
Parisi Samuel Joseph |
VP, Finance (Interim PAO) |
|
2024-02-20 |
4 |
D |
$30.39 |
$19,480 |
D/D |
(641) |
6,459 |
|
- |
|
Parisi Samuel Joseph |
VP, Finance (Interim PAO) |
|
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,872 |
7,100 |
|
- |
|
Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
|
2024-02-20 |
4 |
D |
$30.39 |
$138,943 |
D/D |
(4,572) |
98,608 |
|
- |
|
Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
|
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,297 |
103,180 |
|
- |
|
Jackson Blair Curtis |
EVP, Chief Operating Officer |
|
2024-02-18 |
4 |
D |
$32.18 |
$125,116 |
D/D |
(3,888) |
144,954 |
|
- |
|
Jackson Blair Curtis |
EVP, Chief Operating Officer |
|
2024-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,897 |
148,842 |
|
- |
|
Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
|
2024-02-18 |
4 |
D |
$32.18 |
$42,091 |
D/D |
(1,308) |
271,884 |
|
- |
|
Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
|
2024-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,448 |
273,192 |
|
- |
|
Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
|
2024-02-18 |
4 |
D |
$32.18 |
$60,144 |
D/D |
(1,869) |
152,193 |
|
- |
|
Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
|
2024-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,355 |
154,062 |
|
- |
|
2018 Records found
|
|
Page 2 of 81 |
|
|